Helping local pharma players make overseas foray


  • Corporate News
  • Wednesday, 29 Jul 2020

Duopharma Biotech Bhd group managing director Leonard Ariff Abdul Shatar (pic) said the MS:2424:2012 halal pharmaceuticals standard, which provides general guidelines in the manufacture and handling of halal pharmaceuticals, was rapidly gaining universal acceptance.

KUALA LUMPUR: Malaysia’s global leadership in setting standards for halal pharmaceuticals has served to facilitate the successful entry of domestic pharmaceutical manufacturers into the international halal pharmaceutical market, which is forecast to be valued at US$134bil by 2024.

Duopharma Biotech Bhd group managing director Leonard Ariff Abdul Shatar said the MS:2424:2012 halal pharmaceuticals standard, which provides general guidelines in the manufacture and handling of halal pharmaceuticals, was rapidly gaining universal acceptance.

Meanwhile, its evolution, the MS2424:2019, had significantly expanded the scope of halal certification to address rising demand in biologics and the search for halal vaccines, he said at a webinar on “Embracing a Halal Pharmaceutical Eco-System” organised by the Halal Development Corp (HDC) in collaboration with Duopharma and KPJ Healthcare Bhd.

Hosted by the International Trade and Industry Ministry, it was held yesterday in conjunction with the World Halal Conference (WHC) 2020 webinar series spotlighting the halal pharmaceutical industry, according to a joint statement issued by HDC and Duopharma.

Leonard Ariff said Malaysia’s halal pharmaceutical ecosystem was further boosted by the MS:2424 Halal Pharmaceuticals general guidelines which address the entire supply chain -- from processing to retail.

According to him, hygiene, sanitation and safety are the key pre-requisites in the halal pharmaceutical manufacturing process, in which good manufacturing practices are compulsory requirements in the preparation of halal pharmaceutical products.

“Indeed, these strict requirements for certification translate into an additional layer to drive quality assurance, resulting in a higher benchmark for quality standards.

“Halal certification in the manufacturing process is now acknowledged as a most significant value-add in the pharmaceutical industry, ” he said.

Meanwhile, HDC chief executive officer Hairol Ariffein Sahari said exports of halal pharmaceuticals recorded steady growth, rising to RM401mil in value last year from RM395mil in 2018.

Total halal exports in 2019 stood at RM40.2bil. — Bernama

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

100% readers found this article insightful

Across the site